FDA Proposes Pediatric Labeling Changes for ADHD Drugs

The Food and Drug Administration (FDA) has published a proposal to amend the pediatric labeling for specific Attention Deficit Hyperactivity Disorder (ADHD) medications. This action, identified by docket number FDA-2026-P-2639-0007, aims to update the information provided to healthcare professionals and the public regarding the use of these drugs in pediatric populations. The proposal is currently open for public comment.

Regulated entities, primarily pharmaceutical manufacturers of ADHD drugs, and healthcare providers who prescribe these medications, should review the proposed changes. Interested parties are encouraged to submit comments to the FDA by the specified deadline to influence the final labeling requirements. Failure to comply with updated labeling requirements once finalized could result in regulatory action.